Linezolid Plus Standard of Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
Eligibility criteria
Qualifiers
Staphylococcus aureus (S. aureus) grown from at least one blood culture
Hospitalised at a participating centre
≥18 years old
Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements
Disqualifiers
Administration of the initial drug treatment not feasible within 72 hours since the collection of the first positive blood culture with S. aureus
Documented history of positive blood cultures for S. aureus occurring between 72 hours and 180 days prior to the eligibility assessment
Necrotising fasciitis
Currently receiving linezolid or clindamycin
Trial design
Treatments tested in this trial
- Linezolid 600 mg
- Placebo
Treatment groups
606 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Swiss National Science Foundation
Collaborator
Source ClinicalTrials.gov